Wet macular degeneration
Therapeutic area
Neurology
Rare disease
No
- Definition
- A form of RETINAL degeneration in which abnormal CHOROIDAL NEOVASCULARIZATION occurs under the RETINA and MACULA LUTEA, causing bleeding and leaking of fluid. This leads to bulging and or lifting of the macula and the distortion or destruction of central vision.
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- No
- Listing at source
- Listed
- Condition name
- Wet macular degeneration
- Therapeutic area
- Neurology
- wet macular degeneration
- exudative senile macular degeneration of retina
- wet AMD
- wet ARMD
- wet age related macular degeneration
- Severity
- Moderate
- Genetic
- Hereditary
- Neurology
- Ophthalmology
- MONDO ID
- MONDO:0005417
- Parent condition
- MONDO:0005150
Related records
Broader conditions (17)
- Age-related macular degeneration
- Degeneration of macula and posterior pole
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Disease of genetic or genomic mechanism
- Disorder of orbital region
- Disorder of visual system
- Eye disorder
- Hereditary disease
- Hereditary neurological disease
- Human disease
- Inherited retinal dystrophy
- Macular degeneration
- Nervous system disorder
- Retinal degeneration
- Retinal disorder
Trials (165)
- 4D-150 in Patients With Macular Neovascularization Secondary to Age-Related Macular Degeneration
- 4D-150 in Patients With Neovascular (Wet) Age-Related Macular Degeneration
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUCIA) Primary Efficacy Will be Determined at Week 56
- A 2-year Study of EYP-1901 in Subjects With Wet Age Related Macular Degeneration (wAMD) (LUGANO) Primary Efficacy Will be Determined at Week 56
- A 3-month Study to Assess the Safety and Effectiveness of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- A 3-month Study to Assess the Safety of ONS-5010 in Subjects With Visual Impairment Due to Retinal Disorders
- A 3-month Study to Compare the Safety of ONS-5010 in Vials Versus Pre-filled Syringe in Subjects With Visual Impairment Due to Retinal Disorders
- A 4 Week Study With BI 144807 in Patients >= 50 Years With Wet Age Related Macular Degeneration
- A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- A Clinical Effectiveness Study Examining the Efficacy and Safety of ONS-5010 in Subjects With Neovascular Age-related Macular Degeneration (AMD)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-002)
- A Clinical Trial of EYE201/MK-8748 in People With Macular Degeneration (MK-8748-003)
- A Long-term Follow up Study of EXG102-031 in Participants With wAMD
- A Masked, Placebo-controlled Study to Assess Iptacopan in Age-related Macular Degeneration
- A Population-based Study of Macular Choroidal Neovascularization in a Chinese Population
- A Prospective, Observational, Multicentre, 2 Year Study Evaluating the Use of Eylea (Aflibercept) for the Treatment of Neovascular (Wet) Age-related Macular Degeneration in UK NHS Opthalmology Clinics
- A Randomized, Double Masked, Parallel Group, Dose-finding Study to Evaluate SYL1801 in Patients With Neovascular Age-related Macular Degeneration (AMD)
- A Safety and Efficacy Study of Squalamine Lactate for Injection (MSI-1256F) for "Wet" Age-Related Macular Degeneration
- A Safety Study of KHK4951 in Healthy Volunteers and Patients With Wet Age-Related Macular Degeneration
- A Study of Intravitreal Injections of 2.0mg Ranibizumab in Subjects With Chronic Fluid On OCT Post Multiple Injections With Ranibizumab (Super-dose Anti-VEgf SAVE Trial)
Approved drugs (7)
- Aflibercept
- Bevacizumab gamma
- Brolucizumab
- Faricimab
- Pegaptanib sodium
- Ranibizumab
- Verteporfin
Drugs in development (22)
- Abicipar pegol Phase 1
- AGN-211745 Phase 1
- Avacincaptad pegol Phase 2
- Bevacizumab Phase 3
- Conbercept Phase 2
- Dexamethasone Phase 2
- Dorzolamide Phase 2
- Gildeuretinol Phase 1
- Gildeuretinol acetate Phase 1
- Ixoberogene soroparvovec Phase 1
- Lazucirnon Phase 1
- Lazucirnon hydrochloride Phase 1
- Migaldendranib Phase 1
- Tarcocimab Phase 1
- Tarcocimab tedromer Phase 2
- Tedromer Phase 1
- Tesidolumab Phase 2
- Timolol Phase 2
- Tinlarebant Phase 1
- Triamcinolone Phase 2
Other linked drugs (1)
- Anecortave acetate